|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Gateway Health Alliance |
|---|---|
| Information provided by: | Gateway Health Alliance |
| ClinicalTrials.gov Identifier: | NCT00526682 |
Purpose
Hypothesis: Cissus quadrangularis as well as Irvingia gabonensis are used in weight management and related conditions. This study set out to investigate if a combination of the two could have additional benefits to overweight and obese people.
| Condition | Intervention |
|---|---|
|
Obesity Overweight Dyslipidemia |
Dietary Supplement: Irvingia/cissus combo |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator), Placebo Control, Parallel Assignment, Efficacy Study |
| Official Title: | The Effect of Combining Cissus Quadrangularis and Irvingia Gabonensis on Obesity and Obesity Related Diseases |
| Enrollment: | 72 |
| Study Start Date: | January 2007 |
| Study Completion Date: | April 2007 |
| Arms | Assigned Interventions |
|---|---|
|
1: Active Comparator
Comparison of actives for synergy
|
Dietary Supplement: Irvingia/cissus combo |
To assess and compare the effects of administration of Cissus quadrangularis (Linn) and a Cissus quadrangularis /Irvingia gabonensis combination on body weight blood pressure, fasting blood glucose, plasma total and LDL cholesterol in 72 overweight and obese subjects.
The study was a 10 week randomized, double-blind, placebo-controlled design, involving 72 obese or overweight participants. Participants were randomly divided into three groups (24 participants/ group):
Group 1 - Placebo; Group 2 - Cissus quadrangularis (CQ); Group 3 - Cissus quadrangularis and Irvingia gabonensis (CQ-IG).
The placebo (250mg) or active formulations ((150 mg CQ and 250 mg CQ-IG) were administered twice daily before meals. Weight as well as fasting blood was taken at baseline, and at 4, 8 and 10 weeks.
No major dietary changes or exercises were suggested during the study.
Eligibility| Ages Eligible for Study: | 19 Years to 55 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations More Information
| Study ID Numbers: | GHACT010 |
| Study First Received: | September 6, 2007 |
| Last Updated: | September 6, 2007 |
| ClinicalTrials.gov Identifier: | NCT00526682 |
| Health Authority: | Cameroon: Ministry of Public Health |
|
Antiobesity Weight loss |
|
Body Weight Signs and Symptoms Obesity Metabolic Diseases Weight Loss Nutrition Disorders |
Overnutrition Overweight Metabolic disorder Dyslipidemias Lipid Metabolism Disorders |
